Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ERBB2 Y772_A775dup ERBB2 C805S |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | resistant | Tucatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to Tukysa (tucatinib) in culture (PMID: 30527195). | 30527195 | |
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | resistant | Erlotinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to Tarceva (erlotinib) in culture (PMID: 30527195). | 30527195 | |
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to Tykerb (lapatinib) in culture (PMID: 30527195). | 30527195 | |
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | resistant | Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995). | 28363995 | |
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | predicted - sensitive | Luminespib | Preclinical - Cell culture | Actionable | In a preclinical study, Luminespib (AUY922) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S in culture (PMID: 30527195). | 30527195 | |
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | predicted - sensitive | Ganetespib | Preclinical - Cell culture | Actionable | In a preclinical study, Ganetespib inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S in culture (PMID: 30527195). | 30527195 | |
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | resistant | AZ5104 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to AZ5104 in culture (PMID: 30527195). | 30527195 | |
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | resistant | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995). | 28363995 | |
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | resistant | Dacomitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells co-expressing ERBB2 (HER2) C805S and ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) demonstrated resistance to Vizimpro (dacomitinib) in culture (PMID: 28363995). | 28363995 | |
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | resistant | Osimertinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to Tagrisso (osimertinib) in culture (PMID: 30527195). | 30527195 | |
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | resistant | Poziotinib | Preclinical - Cell culture | Actionable | In a preclinical study, ERBB2 (HER2) C805S was identified as a secondary mutation in transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) that acquired resistance to Poziotinib (HM781-36B) in culture (PMID: 30527195). | 30527195 | |
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | resistant | Pyrotinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to Pyrotinib in culture (PMID: 30527195). | 30527195 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|